Success Story: Advancing Clinical Neurology Through Quantitative Electroencephalography and Stem Cell Research: EB1A Approval Secured for a Clinical Neurology Expert
Client’s Testimonial:
"Thank you for the meticulous preparation of my I-140 package. I truly appreciate the professionalism and efficiency your team has shown throughout this process. It gives me great confidence to have such a dedicated team handling my case."
On July 13th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Clinician / Physician in the Field of Clinical Neurology (Approval Notice).
General Field: Clinical Neurology
Position at the Time of Case Filing: Clinician / Physician
Country of Origin: South Korea
Country of Residence at the Time of Filing: South Korea
Approval Notice Date: July 13th, 2026
Processing Time: 1 month, 29 days (Premium Processing Upgrade Requested)
Case Summary:
The EB-1A (Alien of Extraordinary Ability) category is reserved for individuals who have reached the highest levels of accomplishment in their field through sustained national or international recognition. Successfully demonstrating extraordinary ability requires showing not only a distinguished record of achievement but also objective evidence that the individual's work has influenced the broader field. We are pleased to share another EB-1A approval for a client whose research has advanced clinical neurology through innovative work in quantitative electroencephalography, stroke imaging, and mesenchymal stem cell therapies.
With both an M.D. and an M.S. in neurology, the client has established a career focused on improving the diagnosis and treatment of neurological disorders. At the time of filing, the client was continuing a research career centered on quantitative electroencephalography biomarkers, stroke physiology, regenerative neuroscience, and wearable neurological technologies. Among the client's most influential contributions is research demonstrating how collateral blood flow can predict patient response to endovascular therapy for acute ischemic stroke, alongside studies evaluating the safety and effectiveness of mesenchymal stem cell therapies. These efforts have helped improve clinical decision-making while supporting the development of more advanced diagnostic and therapeutic approaches for neurological diseases.
To demonstrate extraordinary ability, we presented objective evidence showing that the client's work had earned broad recognition from the scientific community. The client had authored 67 peer-reviewed journal articles, including 21 first-authored publications, along with two first-authored book chapters, one first-authored book, and one commercialized patent. More importantly, the publications had generated more than 4,300 citations, reflecting that independent researchers repeatedly relied on the client's findings to advance their own work rather than merely acknowledging them. We also documented that the client had completed at least 56 peer reviews for scholarly journals. In EB-1A adjudications, reviewing the work of fellow researchers is valuable because journals selectively invite experts whose judgment is trusted to evaluate scientific quality, providing independent evidence that the field recognizes the individual's expertise. We further demonstrated that the client's research had progressed beyond academic publication by influencing subsequent technological development and commercialization, illustrating practical impact in addition to scholarly significance.
Another important component of the petition was the inclusion of two independent recommendation letters from internationally recognized experts familiar with the client's work through its influence on the field rather than through personal collaboration. Their letters provided additional context explaining why the client's research had become significant within clinical neurology and how other scientists had benefited from these contributions.
These expert opinions complemented the objective evidence by explaining the broader scientific importance of the client's research and reinforcing that the client's accomplishments represented sustained influence rather than isolated success.
We are delighted that USCIS approved this EB-1A petition. This approval reflects not only the client's sustained record of influential research but also the importance of presenting that record within the legal framework governing extraordinary ability petitions. We congratulate our client on this well-deserved achievement and look forward to seeing future contributions that continue advancing clinical neurology and improving care for patients with neurological disorders.